Condition: Obstetrical Brachial Plexus Palsy · Sponsor: University Hospital, Brest
In children population with obstetrical brachial plexus palsy (OBPP), shoulder musculoskeletal deformity is the main cause of morbidity, with a loss of range of shoulder motion, pain and a reduction in social participation. Some uncontrolled studies shows that early injections of botulinum toxin (BTI) in the internal shoulder rotator muscles (which cause the deformity) are one of the most promising treatment for the prevention of bony deformity. The main objective of this study will be the evaluation of the effectiveness of BTI in the internal shoulder rotator muscles at the age of 12 months in preventing an increase in posterior subluxation of the glenohumeral joint in babies with OBPP (evaluated at the ages of 11 months and 18 months), compared to the Sham group.
This description comes directly from the study's public registry record.
Sylvain Brochard, Pr · (+33) 02 98 22.33.73 · sylvain.brochard@chu-brest.fr
Always discuss trial participation with your own doctor first.
| CHRU Brest | Brest, France | Recruiting |
| Institut Régionnal de Réadaptation Centre de Réadaptation pour enfant | Flavigny-sur-Moselle, France | Not Yet Recruiting |
| ESEAN (Etablissement de Santé pour Enfants et Adolescents de la région Nantaise) | Nantes, France | Not Yet Recruiting |
| CHU Nîmes | Nîmes, France | Recruiting |
| CHU Rennes | Rennes, France | Recruiting |
| CHU St Etienne | Saint-Etienne, France | Not Yet Recruiting |
| Hôpital national de saint maurice | Saint-Maurice, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03198702